TG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) announced that CEO Michael S. Weiss will participate in a virtual fireside chat at the H.C. Wainwright Global Investment Conference from September 12-14, 2022. The chat will be available for on-demand download starting September 12, 2022, at 7:00 AM ET on the conference website and TG's website. TG Therapeutics focuses on developing novel treatments for B-cell diseases, including a Phase 3 program for ublituximab for relapsing forms of multiple sclerosis.

Fireside chat available for on demand download beginning Monday, September 12 2022 at 7:00 AM ET

NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate virtually in a fireside chat at the H.C. Wainwright Global Investment Conference taking place September 12 – 14, 2022.

A webcast of the fireside chat will be available for on demand download beginning on Monday, September 12, 2022, at 7:00 AM ET on the conference website. The webcast will also be available on TG’s website at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS). For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.

CONTACT:

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6

FAQ

When is the TG Therapeutics fireside chat at the H.C. Wainwright Conference?

The TG Therapeutics fireside chat is scheduled for September 12-14, 2022.

What time will the TG Therapeutics fireside chat be available for download?

The chat will be available for on-demand download starting September 12, 2022, at 7:00 AM ET.

Who is participating in the TG Therapeutics fireside chat?

Michael S. Weiss, the Chairman and CEO of TG Therapeutics, will participate in the fireside chat.

What is the focus of TG Therapeutics' business?

TG Therapeutics focuses on developing novel treatments for B-cell diseases.

What investigational drug is TG Therapeutics working on for multiple sclerosis?

TG Therapeutics is developing ublituximab, an investigational monoclonal antibody for treating relapsing forms of multiple sclerosis.